Purpose: The purpose of this study was to determine whether cyclophosphamide (CP) can decrease myocardial and systemic TNF-αexpression and thus protects myocardial I/R injury. Methods: Open chest rats were subjected to 30 min of ischemia followed by 3h, 12h or 24h of reperfusion. Rats were divided into sham group, I/R group and CP group, and each group included 3 timepoint subgroups (3h, 12h and 24h). Plasma TNF-αwas measured by cytometric bead array (CBA) and immunohistochemistry was used to detect TNF-α in myocardium. Results: Compared with I/R group, rats treated with CP showed a significant difference with decreased plasma TNF-α (13.31 ± 2.62 vs 14.13 ± 5.95 pg/mL at 3 h reperfusion, 10.1 ± 2.73 vs 12.54 ± 5.00 pg/mL at 12 h reperfusion, 10.38 ± 5.59 vs 13.00 ± 3.59 pg/mL at 24 h reperfusion, p <0.05 respectively). Immunostaining was less intense with CP injection at each reperfusion time. The score of the intensity of myocardial TNF-αstaining was down regulated.
Conclusions: TNF-α is expressed in the myocardium and plasma after myocardial I/R injury. CP might be a feasible strategy for anti-TNF-α to protect myocardial I/R injury.Keywords: cyclophosphamide, TNF-α, ischemia/reperfusion appeared to be associated with a reduced risk of cardiovascular disease. 1) We recently also disclosed that cyclophosphamide (CP) could improve myocardial function in rats after ischemia reperfusion injury. These findings could help to gain some insight into therapeutic potential of CP in myocardial I/R injury.2) However, the mechanism remains unclear. As we have known TNF-αis released during myocardial I/R from storage sites in tissue mast cells within the myocardium 3) and possibly also from cardiomyocyte itself 4) and the plasma inflammatory cells.5) Presently, we used open-chest ischemia-reperfusion rat model with minimal surgical trauma to further demonstrate whether down-regulation with TNF-α-related inflammatory pathways by CP could reduce myocardial injury after I/R.